VANIPREVIR HCV NS3/4A Protease Inhibitor Treatment of Hepatitis C

被引：0
|
作者：
Hammond, E. [1 ]
Lucas, A. [1 ]
Lucas, M. [1 ]
Phillips, E. [1 ,4 ,5 ]
Gaudieri, S. [2 ,3 ,6 ,7 ]
机构：
[1] Murdoch Univ, Inst Immunol & Infect Dis, Ctr Clin Immunol & Biomed Stat, Murdoch, WA 6150, Australia
[2] Sir Charles Gairdner Hosp, Perth, WA 6000, Australia
[3] Royal Perth Hosp, Perth, WA, Australia
[4] Univ Western Australia, Sch Pathol, Nedlands, WA 6009, Australia
[5] Univ Western Australia, Lab Med & Biomed Biomol & Chem Sci, Nedlands, WA 6009, Australia
[6] Univ Western Australia, Sch Anat & Human Biol, Nedlands, WA 6009, Australia
[7] Univ Western Australia, Ctr Forens Sci, Nedlands, WA 6009, Australia
来源：
DRUGS OF THE FUTURE | 2010年 / 35卷 / 10期
关键词：
MK-7009; CHRONIC HEPATITIS-C; VIRUS NS3/4A PROTEASE; PEGINTERFERON ALPHA-2A; RIBAVIRIN THERAPY; RESISTANCE; INHIBITORS; TELAPREVIR; NOMENCLATURE; ASSOCIATION; MANAGEMENT;
D O I：
10.1358/dof.2010.035.010.1527293
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Protease inhibitors are among a number of new classes of direct-acting antivirals for hepatitis C which, when combined with conventional peginterferon alfa/ribavirin or with other classes of direct-acting antivirals, offer the potential to vastly improve disease outcomes for affected individuals. Early evaluations imply that a number of these agents are well tolerated and produce encouraging rapid declines in plasma viral load. Concerns relate to the rapid development of drug resistance, with resulting viral rebound. Vaniprevir (MK-7009) is a novel inhibitor of genotype 1 proteases with some potency against genotype 2 currently undergoing phase II trials.
引用
收藏
页码：803 / 813
页数：11
相关论文
共 50 条
  • [1] PHARMACOKINETIC INTERACTION OF HCV NS3/4A PROTEASE INHIBITOR VANIPREVIR AND ROSUVASTATIN.
    Orito, Y.
    Iwasa, T.
    Uemura, N.
    Fujimoto, G.
    Yama, S.
    Gao, W.
    Caro, L.
    Fandozzi, C.
    Prucksaritanont, T.
    Anderson, M.
    Butterton, J.
    Hasegawa, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S24 - S25
  • [2] Furaprevir HCV NS3/4A protease inhibitor Treatment of chronic hepatitis C virus infection
    Ghosh, Prithwish
    Nehra, Vandana
    Temesgen, Zelalem
    DRUGS OF THE FUTURE, 2022, 47 (08) : 557 - 565
  • [3] Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
    McCauley, John A.
    McIntyre, Charles J.
    Rudd, Michael T.
    Nguyen, Kevin T.
    Romano, Joseph J.
    Butcher, John W.
    Gilbert, Kevin F.
    Bush, Kimberly J.
    Holloway, M. Katharine
    Swestock, John
    Wan, Bang-Lin
    Carroll, Steven S.
    DiMuzio, Jillian M.
    Graham, Donald J.
    Ludmerer, Steven W.
    Mao, Shi-Shan
    Stahlhut, Mark W.
    Fandozzi, Christine M.
    Trainor, Nicole
    Olsen, David B.
    Vacca, Joseph P.
    Liverton, Nigel J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (06) : 2443 - 2463
  • [4] Telaprevir: A Hepatitis C NS3/4A Protease Inhibitor
    Matthews, Samuel James
    Lancaster, Jason W.
    CLINICAL THERAPEUTICS, 2012, 34 (09) : 1857 - 1882
  • [5] Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C
    Smith, Lisa S.
    Nelson, Michael
    Naik, Sagar
    Woten, Joanna
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (05) : 639 - 648
  • [6] Hepatitis C virus NS3/4A protease
    Kwong, AD
    Kim, JL
    Rao, G
    Lipovsek, D
    Raybuck, SA
    ANTIVIRAL RESEARCH, 1998, 40 (1-2) : 1 - 18
  • [7] Hepatitis C virus NS3/4A protease
    Kwong, AD
    CURRENT OPINION IN INFECTIOUS DISEASES, 1997, 10 (06) : 485 - 490
  • [8] Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
    Lawitz, Eric
    Sulkowski, Mark
    Jacobson, Ira
    Kraft, Walter K.
    Maliakkal, Benedict
    Al-Ibrahim, Mohamed
    Gordon, Stuart C.
    Kwo, Paul
    Rockstroh, Juergen Kurt
    Panorchan, Paul
    Miller, Michelle
    Caro, Luzelena
    Barnard, Richard
    Hwang, Peggy May
    Gress, Jacqueline
    Quirk, Erin
    Mobashery, Niloufar
    ANTIVIRAL RESEARCH, 2013, 99 (03) : 214 - 220
  • [9] Synthesis of Grazoprevir, a Potent NS3/4a Protease Inhibitor for the Treatment of Hepatitis C Virus
    Xu, Feng
    Kim, Jungchul
    Waldman, Jacob
    Wang, Tao
    Devine, Paul
    ORGANIC LETTERS, 2018, 20 (22) : 7261 - 7265
  • [10] TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection
    Tsantrizos, Youla S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (08) : 871 - 881
12345